saxagliptin


Also found in: Medical, Wikipedia.

sax·a·glip·tin

 (săk′sə-glĭp′tn)
n.
An oral hypoglycemic drug, C18H25N3O2, used to treat type 2 diabetes.

[saxa-, of unknown origin + -gliptin, hypoglycemic drug suffix; see linagliptin.]
Translations

saxagliptin

n saxagliptina
Mentioned in ?
References in periodicals archive ?
The combination of saxagliptin and dapagliflozin has the potential to confer significant benefits in glycaemic control without the risk of weight gain and hypoglycemia, which may be associated with other medications used to treat type 2 diabetes.
The US Food and Drug Administration (FDA) has approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and exercise to improve glycaemic control in adults with type-2 diabetes (T2D).
The United States Food and Drug Administration (FDA) has approved UK-based Astrazeneca's Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and exercise to improve glycaemic control in adults with type-2 diabetes (T2D), it was reported yesterday.
AstraZeneca Plc (LON:AZN), a global, science-led biopharmaceutical company, announced on Friday that approval by the US Food and Drug Administration (FDA) of Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and exercise to improve glycaemic control in adults with type-2 diabetes (T2D).
Presentations assessing the combination of dapagliflozin and saxagliptin, include 24-week results of dapagliflozin as add- on therapy to saxagliptin, in addition to metformin compared with insulin in patients with or without sulfonylurea therapy.
Saxagliptin was reported to increase the rate of hospitalization for HF [16] in the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-Thrombolysis in Myocardial Infarction (TIMI) 53 trial.
Hence, the present study was planned to evaluate wound healing property of linagliptin, saxagliptin, sitagliptin, and vildagliptin on excised wounds in non-diabetic Wistar albino rats.
To rein in the levels, diabetics take a group of pills called DPP4 inhibitors: sitagliptin, vildagliptin, saxagliptin etc.
Recent CV outcomes trials showed no increase in the risk of MACE with alogliptin, saxagliptin, and sitagliptin.
The new drug is indicated as an adjunct to diet and exercise to improve the control of blood sugar levels in adults with type 2 diabetes who have inadequate blood glucose control with dapagliflozin (10 mg) alone or who are already treated with dapagliflozin and saxagliptin. Qtern combines two anti-hyperglycemic agents with complementary mechanisms in a once-daily tablet: dapagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor.
The aim of our study was therefore to investigate whether the DPP-4 inhibitor saxagliptin modifies the expression of selected inflammatory biomarkers, primarily in isolated peripheral blood mononuclear cells (PBMCs) and in circulating leukocytes in patients with stable coronary artery disease (CAD) and T2DM.
There is no doubt that major cardiovascular events (MACE), death, and heart failure are indeed robust clinical endpoints; however, some of the results such as the potential heart failure signal for the dipeptidyl peptidase 4 (DPP-4) inhibitor saxagliptin in SAVORTIMI 53 or the pronounced cardiovascular benefit of the sodium-dependent glucose transporter 2 (SGLT-2) inhibitors empagliflozin and canagliflozin were rather surprising.